SpectraCure AB Quarterly report (1 April to 30 June) 2019

Second quarter (1 April – 30 June 2019)

  •  Net sales for the quarter amounted to TSEK 0 (0).
  •  Other income amounted to TSEK 663 (406).
  •  Profit after tax amounted to TSEK -4 149 (-4 028).
  •  Corresponding to SEK -0,05 (-0,07) per share.
  •  Operating cash flow was TSEK -3 547 (-2 977).
  •  Cash as of 30 June amounted to TSEK 32 619 (7 025).
  •  Equity ratio 79 (83)%.

Half-year (1 January – 30 June 2019) 

  •  Net sales for the quarter amounted to TSEK 0 (0).
  •  Other income amounted to TSEK 1 313 (687).
  •  Profit after tax amounted to TSEK -6 925 (-6 650).
  •  Corresponding to SEK -0,08 (-0,11) per share.
  •  Operating cash flow was TSEK -3 576 (-4 364).

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on August 21st, 2019 14.00.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region

Tags:

About Us

SpectraCure's business concept is to, with its proprietary and patent-pending system, cure internal cancer tumors, prolong survival for cancer patients, and to act as complementary treatment options for other cancer treatments.

Subscribe

Media

Media

Documents & Links